Skip to main content
    C

    Champions Oncology Inc (CSBR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.56
    -0.14 (-3.08%)

    Market Cap: $65.49M

    Last updated: Nov 17, 2026 at 10:50 AM ET

    Champions Oncology Inc (CSBR) Financials: Revenue, Profit and Cash Flow

    Updated Sep 10, 2026. Financial statements from company filings, amounts in US dollars.

    Champions Oncology reported revenue of $59.42M for the fiscal year ended Apr 30, 2026, up 4.4% from the year before. That year, net income was -$1.18M with a net margin of -2.0%, operating cash flow was -$4.47M and free cash flow was -$5.04M. The quarter ended Jul 31, 2026 had revenue of $15.23M and net income of -$426.00K.

    Revenue and Margins

    The operating margin was -1.9% in the fiscal year ended Apr 2026. Over the 9 years to Apr 2026, revenue grew from $15.41M, a compound annual rate of 16.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Apr 2026$59.42M+4.4%48.0%-1.9%-2.0%
    Apr 2025$56.94M+13.5%50.1%8.0%8.3%
    Apr 2024$50.16M-6.9%41.4%-14.7%-14.5%
    Apr 2023$53.87M+9.7%45.2%-9.8%-9.9%
    Apr 2022$49.11M+19.7%51.9%1.2%1.1%
    Apr 2021$41.04M+27.8%47.7%0.9%0.9%
    Apr 2020$32.12M+18.7%47.1%-6.0%-6.5%
    Apr 2019$27.07M+33.7%100.0%1.0%0.5%
    Apr 2018$20.24M+31.3%100.0%-6.7%-7.3%
    Apr 2017$15.41MN/A100.0%-44.2%-44.7%
    Annual, fiscal years ended Apr 2017 to Apr 2026

    Income Statement

    In the fiscal year ended Apr 2026, the company posted a net loss after a profit the year before. In the quarter ended Jul 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020Apr 2019Apr 2018Apr 2017
    Revenue$59.42M$56.94M$50.16M$53.87M$49.11M$41.04M$32.12M$27.07M$20.24M$15.41M
    Cost of revenue$30.90M$28.39M$29.40M$29.53M$23.63M$21.45M$17.00M$0$0$0
    Gross profit$28.52M$28.55M$20.75M$24.34M$25.48M$19.59M$15.12M$27.07M$20.24M$15.41M
    Research and development$9.08M$6.83M$9.54M$11.54M$9.37M$7.20M$5.85M$4.80M$4.40M$4.29M
    Operating income-$1.14M$4.55M-$7.36M-$5.26M$607.00K$366.00K-$1.92M$270.00K-$1.35M-$6.81M
    Net income-$1.18M$4.70M-$7.28M-$5.33M$548.00K$362.00K-$2.09M$128.00K-$1.48M-$6.88M
    EBITDA$448.00K$6.27M-$5.44M-$3.02M$2.21M$1.62M-$1.14M$837.00K-$1.08M-$6.70M
    Fiscal years ended Apr 2017 to Apr 2026

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Revenue$15.23M$13.84M$16.56M$15.04M$13.99M$12.36M$17.04M$13.49M$14.06M$14.00M$12.02M$11.57M
    Gross profit$7.70M$7.03M$7.72M$7.77M$6.00M$5.08M$10.42M$6.06M$6.99M$6.75M$4.17M$4.96M
    Operating income-$409.00K-$522.00K-$276.00K$185.00K-$527.00K-$2.01M$4.50M$732.00K$1.33M-$272.00K-$2.58M-$1.96M
    Net income-$426.00K-$667.00K-$279.00K$237.00K-$466.00K-$1.83M$4.50M$728.00K$1.31M-$109.00K-$2.53M-$2.07M
    Last 12 quarters

    Balance Sheet

    As of Apr 2026, cash and equivalents of $4.87M were 18.0% of total assets of $26.99M, against total liabilities of $22.92M.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020Apr 2019Apr 2018Apr 2017
    Total assets$26.99M$32.34M$26.13M$34.31M$35.38M$27.59M$20.75M$11.27M$8.08M$8.01M
    Current assets$19.22M$22.36M$13.64M$19.46M$19.66M$12.63M$13.50M$7.92M$5.06M$5.87M
    Cash and equivalents$4.87M$9.79M$2.62M$10.12M$9.01M$4.69M$8.34M$3.24M$856.00K$3.29M
    Total liabilities$22.92M$28.57M$28.04M$29.68M$26.28M$20.16M$15.65M$9.03M$8.07M$7.61M
    Short-term debtN/A$1.47M$1.34M$1.21M$1.05M$818.00K$628.00K$16.00K$26.00K$25.00K
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/A$16.00K$38.00K
    Shareholder equity$3.94M$3.77M-$1.90M$4.64M$9.10M$7.43M$5.10M$2.24M$3.00K$400.00K
    Fiscal years ended Apr 2017 to Apr 2026

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Total assets$33.29M$26.99M$28.45M$30.16M$30.55M$32.34M$30.63M$25.24M$24.93M$26.13M$26.79M$28.29M
    Total liabilities$28.83M$22.92M$24.07M$25.93M$27.01M$28.57M$25.16M$24.56M$25.27M$28.04M$28.84M$28.20M
    Cash and equivalents$4.36M$4.87M$7.13M$8.52M$10.32M$9.79M$3.20M$2.75M$2.89M$2.62M$4.47M$5.51M
    Shareholder equity$3.89M$3.94M$4.28M$4.17M$3.51M$3.77M$5.47M$681.00K-$332.00K-$1.90M-$2.06M$93.00K
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Apr 2026.

    Annual

    Line itemApr 2026Apr 2025Apr 2024Apr 2023Apr 2022Apr 2021Apr 2020Apr 2019Apr 2018Apr 2017
    Operating cash flow-$4.47M$7.39M-$6.14M$3.97M$6.50M-$1.68M$2.90M$1.86M-$1.23M-$2.84M
    Capital expenditures$564.00K$389.00K$836.00K$2.87M$2.38M$3.28M$2.22M$834.00K$1.23M$766.00K
    Free cash flow-$5.04M$7.00M-$6.97M$1.10M$4.11M-$4.96M$685.00K$1.03M-$2.46M-$3.61M
    Share repurchasesN/A$0$634.00K$74.00K$0N/AN/AN/AN/AN/A
    Investing cash flow-$540.00K-$389.00K-$836.00K-$2.87M-$2.38M-$3.17M-$2.22M-$834.00K-$1.23M-$766.00K
    Financing cash flow$99.00K$170.00K-$527.00K$11.00K$207.00K$1.20M$4.42M$1.20M$13.00K$4.32M
    Fiscal years ended Apr 2017 to Apr 2026

    Quarterly

    Line itemJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023
    Operating cash flow-$492.00K-$2.00M-$1.34M-$1.74M$600.00K$6.87M$490.00K-$283.00K$311.00K-$1.82M-$919.00K$589.00K
    Capital expenditures$55.00K$239.00K$37.00K$242.00K$46.00K$253.00K$42.00K$94.00K$0$3.00K$92.00K$79.00K
    Free cash flow-$547.00K-$2.24M-$1.38M-$1.98M$554.00K$6.62M$448.00K-$377.00K$311.00K-$1.82M-$1.01M$510.00K
    Last 12 quarters

    Frequently Asked Questions About CSBR

    What is Champions Oncology's annual revenue?

    Champions Oncology reported revenue of $59.42M for the fiscal year ended Apr 30, 2026.

    How fast is Champions Oncology's revenue growing?

    Revenue was up 4.4% for the fiscal year ended Apr 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 3.3%.

    Is Champions Oncology profitable?

    No. Champions Oncology reported net income of -$1.18M for the fiscal year ended Apr 30, 2026, with a net margin of -2.0%.

    How much free cash flow does CSBR generate?

    For the fiscal year ended Apr 30, 2026, operating cash flow of -$4.47M minus capital expenditures of $564.00K produced free cash flow of -$5.04M.

    How much debt does Champions Oncology have?

    The balance sheet dated Apr 30, 2026 reported cash and equivalents of $4.87M.